Provides contract research, development, and manufacturing (CRDMO) services for the pharmaceutical, biotech, and medical device industries. Now — the numbers.
The stock trades below its recent peak — about 8% off the top. A pullback, not a collapse.
It pays out $0.31 per share each year — regular cash for whoever holds the stock.
Getting in and out without moving the price could prove difficult.
Against everything we grade, WUXAY lands near the bottom. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: revenue and profit, the growth trend, the balance sheet, the revenue breakdown.